Memo Therapeutics AG announces appointment of Dr. George Badita as Chief Medical Officer and Lars Spenger as Head of Finance and Administration

Schlieren, Switzerland – June 16, 2020 – Memo Therapeutics AG an innovator in the field of antibody discovery and development, announced today the appointment of Dr. George Badita as Chief Medical Officer and Lars Spenger as Head of Finance and Administration.

Dr. Badita is an MD, board certified in Infectious Diseases, with over 30 years of experience in life sciences in hospital, academic, and pharmaceutical industry settings. He has over 20 years of experience in drug development, particularly in Anti-infectives, as well as in Oncology, Immunology and Respiratory areas. He held successive Clinical Development senior positions at various European and US companies and contributed to bring to market several anti-infectives.

Lars Spenger is a chartered certified accountant, with over 10 years of work experience in corporate finance, private equity, and various operational roles in industry settings, most recently as CFO and previously as Head of Group Controlling and M&A.

“We are very pleased to welcome George and Lars to Memo Therapeutics as key members of the leadership team” declared Dr. Karsten Fischer, CEO. “George brings his extensive expertise in Translational Medicine and Clinical Drug Development as the company is in a pivotal stage of growth and prepares to transition to a clinical-stage organization. Lars will be instrumental in supporting the company in its upcoming growth phase and brings a successful track record in raising funds and managing private and public companies.” continued Dr. Karsten Fischer.

About Memo Therapeutics AG
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.